English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, January 22, 2019
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Friday, January 18, 2019
エーザイ、希望退職者の募集の結果に関するお知らせ
Eisai's Notification Regarding Results of Voluntary Retirement Program
Tuesday, January 15, 2019
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
エーザイ、米国臨床腫瘍学会 2019年消化器がんシンポジウムにおいて「レンビマ(R)」(レンバチニブ)の肝細胞がんを対象とした臨床第III相試験(REFLECT試験)の最新解析結果を発表
エーザイ、新たな不眠障害治療薬「レンボレキサント」が米国において新薬承認申請を提出
Friday, January 4, 2019
エーザイ、抗てんかん剤ペランパネルが中国当局より部分てんかん併用療法に係る適応の新薬承認申請について優先審査に指定
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: